Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610226 · ClinicalTrials.gov registry record
Post-refractive IOL Outcomes With Clareon TruPlus
A clinical trial, sponsored by Laser Defined Vision.
- Recruiting
- Registry status
- 35
- Enrollment target
NCT07610226: Recruiting study, sponsored by Laser Defined Vision.
NCT07610226 is a clinical trial that is actively recruiting participants, run by Laser Defined Vision. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07610226 is actively recruiting participants, sponsored by Laser Defined Vision.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
Study Summary
This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.
Primary Outcome
Measured using standard ETDRS charts and recorded in logMAR
Interventions
- DEVICE Clareon TruPlus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2027-06-23 |
What NCT07610226 shows while recruiting
NCT07610226 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Clareon TruPlus is the first listed.
NCT07610226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07610226 about?
NCT07610226 is a clinical study titled "Post-refractive IOL Outcomes With Clareon TruPlus". This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the P...
What is the current status of trial NCT07610226?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2026-06-23. Estimated completion is 2027-06-23.
What interventions are being tested in trial NCT07610226?
The interventions under investigation include: Clareon TruPlus (DEVICE).
Who is sponsoring clinical trial NCT07610226?
This trial is sponsored by Laser Defined Vision, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI